tiprankstipranks
Vertex Pharmaceuticals Inc. (MX:VRTX)
NASDAQ:VRTX
Mexico Market
VRTX
Vertex Pharmaceuticals
RESEARCH TOOLSreports

Vertex Pharmaceuticals (VRTX) Stock Forecast & Price Target

― Followers
See the Price Targets and Ratings of:

VRTX Analyst Ratings

Moderate Buy
27Ratings
Moderate Buy
21 Buy
5 Hold
1 Sell
Based on 27 analysts giving stock ratings to
Vertex
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VRTX Stock 12 Month Forecast

Average Price Target

$9,783.64
Based on 27 Wall Street analysts offering 12 month price targets for Vertex Pharmaceuticals in the last 3 months. The average price target is $9,783.64 with a high forecast of $11,415.76 and a low forecast of $6,128.09. The average price target represents a ― change from the last price of ―.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6127":"$6,127","11416":"$11,416","7449.25":"$7,449.3","8771.5":"$8,771.5","10093.75":"$10,093.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":11415.76496444,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$11K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9783.636391236523,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6128.0946895,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6127,7449.25,8771.5,10093.75,11416],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8783.6,8986.074228033847,9188.548456067692,9391.02268410154,9593.496912135384,9795.971140169231,9998.445368203078,10200.919596236923,10403.39382427077,10605.868052304617,10808.342280338462,11010.816508372309,11213.290736406154,{"y":11415.76496444,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8783.6,8860.525876248963,8937.451752497927,9014.37762874689,9091.303504995854,9168.229381244817,9245.15525749378,9322.081133742744,9399.007009991707,9475.93288624067,9552.858762489634,9629.784638738596,9706.71051498756,{"y":9783.636391236523,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8783.6,8579.33036073077,8375.06072146154,8170.791082192308,7966.521442923077,7762.251803653846,7557.982164384615,7353.712525115385,7149.442885846154,6945.173246576923,6740.903607307692,6536.633968038461,6332.36432876923,{"y":6128.0946895,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8335,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8765.049,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7323.11,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7449,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7779.18,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8020,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8242.959,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7731.22,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8370,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8000,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7501,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7700,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8783.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$11,416Average Price Target$9,784Lowest Price Target$6,128
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on MX:VRTX
Salveen Richter
Goldman Sachs
Goldman Sachs
$11,223.17→$11,415.76
Buy
―
Reiterated
07/20/26
Analysts' Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Valneva (VALN)
Citi Analyst forecast on MX:VRTX
Geoff Meacham
Citi
Citi
$10,242.67
Buy
―
Reiterated
07/15/26
Vertex Pharmaceuticals (VRTX) Gets a Buy from Citi
Truist Financial Analyst forecast on MX:VRTX
Danielle Brill
Truist Financial
Truist Financial
$9,489.79→$9,804.95
Buy
―
Reiterated
07/13/26
Vertex Pharmaceuticals price target raised to $560 from $542 at TruistVertex Pharmaceuticals price target raised to $560 from $542 at Truist
Wells Fargo Analyst forecast on MX:VRTX
Mohit Bansal
Wells Fargo
Wells Fargo
$9,629.86
Buy
―
Assigned
07/13/26
Analysts Conflicted on These Healthcare Names: Exelixis (NASDAQ: EXEL) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Bank of America Securities Analyst forecast on MX:VRTX
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$10,470.29→$10,505.31
Buy
―
Reiterated
07/13/26
Vertex Pharmaceuticals: Buy Rating Reaffirmed as Analyst Lifts Price Target from $598 to $600 on Robust CF Growth and Emerging Nephrology/Endocrinology Upside
BMO Capital Analyst forecast on MX:VRTX
Evan Seigerman
BMO Capital
BMO Capital
$10,505.31
Buy
―
Reiterated
07/13/26
BMO Capital Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
UBS Analyst forecast on MX:VRTX
Michael Yee
UBS
UBS
$9,542.32→$10,242.67
Buy
―
Assigned
07/13/26
Vertex Pharmaceuticals price target raised to $585 from $545 at UBSVertex Pharmaceuticals price target raised to $585 from $545 at UBS
Maxim Group Analyst forecast on MX:VRTX
Naz Rahman
Maxim Group
Maxim Group
$10,067.58
Buy
―
Reiterated
07/09/26
Vertex: Buy Rating Reaffirmed as Crinetics Deal Broadens Revenue Base; $575 Price Target Maintained
Jefferies Analyst forecast on MX:VRTX
Akash Tewari
Jefferies
Jefferies
$10,680.39
Buy
―
Reiterated
07/08/26
Analysts Conflicted on These Healthcare Names: Certara (NASDAQ: CERT), Nurix Therapeutics (NASDAQ: NRIX) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Barclays Analyst forecast on MX:VRTX
Eliana Merle
Barclays
Barclays
$10,767.94
Buy
―
Reiterated
07/08/26
Vertex Pharmaceuticals (VRTX) Receives a Buy from Barclays
William Blair Analyst forecast on MX:VRTX
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
07/07/26
Vertex’s $10 Billion Crinetics Acquisition Adds Endocrinology Growth Pillars, Supporting Long-Term Buy Thesis
H.C. Wainwright Analyst forecast on MX:VRTX
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$11,223.17
Buy
―
Reiterated
07/07/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX) and Waters (NYSE: WAT)
Needham Analyst forecast on MX:VRTX
Joseph Stringer
Needham
Needham
―
Hold
―
Reiterated
07/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: HUTCHMED (NASDAQ: HCM), Axsome Therapeutics (NASDAQ: AXSM) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Evercore ISI Analyst forecast on MX:VRTX
Cory Kasimov
Evercore ISI
Evercore ISI
$9,367.23
Buy
―
Reiterated
07/07/26
Analysts Are Bullish on These Healthcare Stocks: Insmed (INSM), Biogen (BIIB)
RBC Capital Analyst forecast on MX:VRTX
Brian Abrahams
RBC Capital
RBC Capital
$9,507.3→$9,980.04
Buy
―
Reiterated
07/07/26
Vertex Pharmaceuticals price target raised to $570 from $543 at RBC CapitalVertex Pharmaceuticals price target raised to $570 from $543 at RBC Capital
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on MX:VRTX
Salveen Richter
Goldman Sachs
Goldman Sachs
$11,223.17→$11,415.76
Buy
―
Reiterated
07/20/26
Analysts' Top Healthcare Picks: Vertex Pharmaceuticals (VRTX), Valneva (VALN)
Citi Analyst forecast on MX:VRTX
Geoff Meacham
Citi
Citi
$10,242.67
Buy
―
Reiterated
07/15/26
Vertex Pharmaceuticals (VRTX) Gets a Buy from Citi
Truist Financial Analyst forecast on MX:VRTX
Danielle Brill
Truist Financial
Truist Financial
$9,489.79→$9,804.95
Buy
―
Reiterated
07/13/26
Vertex Pharmaceuticals price target raised to $560 from $542 at TruistVertex Pharmaceuticals price target raised to $560 from $542 at Truist
Wells Fargo Analyst forecast on MX:VRTX
Mohit Bansal
Wells Fargo
Wells Fargo
$9,629.86
Buy
―
Assigned
07/13/26
Analysts Conflicted on These Healthcare Names: Exelixis (NASDAQ: EXEL) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Bank of America Securities Analyst forecast on MX:VRTX
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$10,470.29→$10,505.31
Buy
―
Reiterated
07/13/26
Vertex Pharmaceuticals: Buy Rating Reaffirmed as Analyst Lifts Price Target from $598 to $600 on Robust CF Growth and Emerging Nephrology/Endocrinology Upside
BMO Capital Analyst forecast on MX:VRTX
Evan Seigerman
BMO Capital
BMO Capital
$10,505.31
Buy
―
Reiterated
07/13/26
BMO Capital Reaffirms Their Buy Rating on Vertex Pharmaceuticals (VRTX)
UBS Analyst forecast on MX:VRTX
Michael Yee
UBS
UBS
$9,542.32→$10,242.67
Buy
―
Assigned
07/13/26
Vertex Pharmaceuticals price target raised to $585 from $545 at UBSVertex Pharmaceuticals price target raised to $585 from $545 at UBS
Maxim Group Analyst forecast on MX:VRTX
Naz Rahman
Maxim Group
Maxim Group
$10,067.58
Buy
―
Reiterated
07/09/26
Vertex: Buy Rating Reaffirmed as Crinetics Deal Broadens Revenue Base; $575 Price Target Maintained
Jefferies Analyst forecast on MX:VRTX
Akash Tewari
Jefferies
Jefferies
$10,680.39
Buy
―
Reiterated
07/08/26
Analysts Conflicted on These Healthcare Names: Certara (NASDAQ: CERT), Nurix Therapeutics (NASDAQ: NRIX) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Barclays Analyst forecast on MX:VRTX
Eliana Merle
Barclays
Barclays
$10,767.94
Buy
―
Reiterated
07/08/26
Vertex Pharmaceuticals (VRTX) Receives a Buy from Barclays
William Blair Analyst forecast on MX:VRTX
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
07/07/26
Vertex’s $10 Billion Crinetics Acquisition Adds Endocrinology Growth Pillars, Supporting Long-Term Buy Thesis
H.C. Wainwright Analyst forecast on MX:VRTX
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$11,223.17
Buy
―
Reiterated
07/07/26
Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (NASDAQ: VRTX) and Waters (NYSE: WAT)
Needham Analyst forecast on MX:VRTX
Joseph Stringer
Needham
Needham
―
Hold
―
Reiterated
07/07/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: HUTCHMED (NASDAQ: HCM), Axsome Therapeutics (NASDAQ: AXSM) and Vertex Pharmaceuticals (NASDAQ: VRTX)
Evercore ISI Analyst forecast on MX:VRTX
Cory Kasimov
Evercore ISI
Evercore ISI
$9,367.23
Buy
―
Reiterated
07/07/26
Analysts Are Bullish on These Healthcare Stocks: Insmed (INSM), Biogen (BIIB)
RBC Capital Analyst forecast on MX:VRTX
Brian Abrahams
RBC Capital
RBC Capital
$9,507.3→$9,980.04
Buy
―
Reiterated
07/07/26
Vertex Pharmaceuticals price target raised to $570 from $543 at RBC CapitalVertex Pharmaceuticals price target raised to $570 from $543 at RBC Capital
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
GKOSGlaukos
ARDXArdelyx
STOKStoke Therapeutics
MIRMMirum Pharmaceuticals
CSTLCastle Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vertex Pharmaceuticals

3 Months
Mohit BansalWells Fargo
Success Rate
24/33 ratings generated profit
73%
Average Return
+6.99%
Copying Mohit Bansal's trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +6.99% per trade.
1 Year
Mohit BansalWells Fargo
Success Rate
24/33 ratings generated profit
73%
Average Return
+13.54%
Copying Mohit Bansal's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +13.54% per trade.
2 Years
Geoff MeachamCiti
Success Rate
35/41 ratings generated profit
85%
Average Return
+17.09%
Copying Geoff Meacham's trades and holding each position for 2 Years would result in 85.37% of your transactions generating a profit, with an average return of +17.09% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VRTX Analyst Recommendation Trends

Rating
Mar 26
Apr 26
May 26
Jun 26
Jul 26
Strong Buy
0
0
0
0
0
Buy
56
45
42
33
47
Hold
11
13
11
9
9
Sell
0
0
0
0
1
Strong Sell
0
0
0
0
0
total
67
58
53
42
57
In the current month, VRTX has received 47 Buy Ratings, 9 Hold Ratings, and 1 Sell Ratings. VRTX average Analyst price target in the past 3 months is 9,783.64.
Each month's total comprises the sum of three months' worth of ratings.

VRTX Financial Forecast

VRTX Earnings Forecast

Next quarter’s earnings estimate for VRTX is $82.99 with a range of $69.86 to $90.52. The previous quarter’s EPS was $78.26. VRTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year VRTX has Performed in-line its overall industry.
Next quarter’s earnings estimate for VRTX is $82.99 with a range of $69.86 to $90.52. The previous quarter’s EPS was $78.26. VRTX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year VRTX has Performed in-line its overall industry.

VRTX Sales Forecast

Next quarter’s sales forecast for VRTX is $56.53B with a range of $54.79B to $57.93B. The previous quarter’s sales results were $52.74B. VRTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year VRTX has Performed in-line its overall industry.
Next quarter’s sales forecast for VRTX is $56.53B with a range of $54.79B to $57.93B. The previous quarter’s sales results were $52.74B. VRTX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.70% of the time in the same period. In the last calendar year VRTX has Performed in-line its overall industry.

VRTX Stock Forecast FAQ

What is MX:VRTX’s average 12-month price target, according to analysts?
Based on analyst ratings, Vertex Pharmaceuticals Inc.’s 12-month average price target is 9,783.64.
    What is MX:VRTX’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for MX:VRTX, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Vertex Pharmaceuticals Inc. a Buy, Sell or Hold?
        Vertex Pharmaceuticals Inc. has a consensus rating of Moderate Buy, which is based on 21 buy ratings, 5 hold ratings and 1 sell ratings.
          What is Vertex Pharmaceuticals Inc.’s share price target?
          The average share price target for Vertex Pharmaceuticals Inc. is 9,783.64. This is based on 27 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $11,415.76 ,and the lowest forecast is $6,128.09. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Vertex Pharmaceuticals Inc.?
            Vertex Pharmaceuticals Inc.’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 27 Wall Streets Analysts.
              How can I buy shares of Vertex Pharmaceuticals Inc.?
              To buy shares of MX:VRTX, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.